OTCMKTS:BPMUF

Basilea Pharmaceutica (BPMUF) Stock Forecast, Price & News

$50.00

0.00 (0.00%)

(As of 09/21/2023 ET)

Compare

Today's Range: $50.00
▼
$50.00
50-Day Range: $50.00
▼
$50.00
52-Week Range: $50.00
▼
$50.00

Volume: N/A
Average Volume: N/A
Market Capitalization: $592.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Analyst Ratings Chart Competitors Headlines Short Interest

About Basilea Pharmaceutica (OTCMKTS:BPMUF) Stock

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase ½ clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

BPMUF Price History

30 days | 90 days | 365 days | Advanced Chart

BPMUF Stock News Headlines

August 15, 2023 | finance.yahoo.com

Basilea reports strong revenue and profit growth in first half-year 2023

August 4, 2023 | markets.businessinsider.com

Basilea Pharma Submits NDA For Antibiotic Ceftobiprole

September 22, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

August 4, 2023 | finance.yahoo.com

Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

June 8, 2023 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

April 18, 2023 | finance.yahoo.com

Basilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprole

February 14, 2023 | markets.businessinsider.com

Basilea Pharmaceutica Posts FY Profit

February 14, 2023 | finance.yahoo.com

Basilea reports strong financial results 2022 based on successful implementation of new strategy

September 22, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

February 7, 2023 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer

January 24, 2023 | markets.businessinsider.com

Basilea Pharma Expects Net Profit In FY22

January 24, 2023 | finance.yahoo.com

Basilea reports preliminary operating profit for 2022, significantly above guidance

January 11, 2023 | finance.yahoo.com

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

January 9, 2023 | finance.yahoo.com

Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea

December 28, 2022 | finance.yahoo.com

Basilea announces repayment of 2022 convertible bonds

December 23, 2022 | finance.yahoo.com

Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan

December 19, 2022 | finance.yahoo.com

Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen

December 14, 2022 | finance.yahoo.com

Here's Why Momentum in Basilea Pharmaceutica AG (BPMUF) Should Keep going

December 9, 2022 | finance.yahoo.com

Is Basilea Pharmaceutica (BPMUF) Outperforming Other Medical Stocks This Year?

November 28, 2022 | finance.yahoo.com

Here's What Could Help Basilea Pharmaceutica AG (BPMUF) Maintain Its Recent Price Strength

November 2, 2022 | nasdaq.com

Basilea Pharma To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-SevenTherapeutics

November 2, 2022 | finance.yahoo.com

Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics

October 13, 2022 | finance.yahoo.com

Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022

October 8, 2022 | reuters.com

Basilea Pharmaceutica AG

September 21, 2022 | finance.yahoo.com

Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

September 20, 2022 | finance.yahoo.com

Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance

September 8, 2022 | finance.yahoo.com

Basilea announces sale of preclinical oncology program to Nodus Oncology

See More Headlines

Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

BPMUF Company Calendar

Today: 9/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BPMUF
CUSIP: N/A
CIK: N/A
Web: www.basilea.com
Phone: (161) 606-1111
Fax: 41-61-606-1112
Employees: 143
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.34
Quick Ratio: 2.02

Sales & Book Value

Annual Sales: $154.86 million
Price / Sales: 3.83
Cash Flow: $1.17 per share
Price / Cash Flow: 42.69
Book Value: ($1.83) per share
Price / Book: -27.32

Miscellaneous

Outstanding Shares: 11,850,000
Free Float: N/A
Market Cap: $592.50 million
Optionable: Not Optionable
Beta: 0.84

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. David Veitch (Age 58)
Chief Exec. Officer
Comp: $1.37M

Mr. Adesh Kaul (Age 49)
Chief Financial Officer

Dr. Gerrit Hauck Ph.D. (Age 59)
Chief Technology Officer

Dr. Laurenz Kellenberger Ph.D. (Age 56)
Chief Scientific Officer

Dr. Marc Engelhardt M.D. (Age 59)
Chief Medical Officer

Dr. Peer Nils Schroder
Head of Corp. Communications & Investor Relations

Mr. Damian Heller (Age 57)
Gen. Counsel & Corp. Sec.

Ms. Ursula Eberhardt (Age 61)
Head of Global HR

Mr. Mark Jones (Age 55)
Head of Project Management & Preclinical Devel.

Mr. Peter Bielmeier Ph.D. (Age 56)
Head of Global Quality Management

Key Competitors

View All Competitors

BPMUF Stock - Frequently Asked Questions

Should I buy or sell Basilea Pharmaceutica stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPMUF shares.
View BPMUF analyst ratings or view top-rated stocks.
How have BPMUF shares performed in 2023?: Basilea Pharmaceutica's stock was trading at $52.00 at the beginning of 2023. Since then, BPMUF stock has decreased by 3.8% and is now trading at $50.00.
View the best growth stocks for 2023 here.
Are investors shorting Basilea Pharmaceutica?: Basilea Pharmaceutica saw a decline in short interest in August. As of August 31st, there was short interest totaling 276,400 shares, a decline of 9.2% from the August 15th total of 304,300 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
View Basilea Pharmaceutica's Short Interest.
What is Basilea Pharmaceutica's stock symbol?: Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."

How do I buy shares of Basilea Pharmaceutica?: Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Basilea Pharmaceutica's stock price today?: One share of BPMUF stock can currently be purchased for approximately $50.00.
How much money does Basilea Pharmaceutica make?: Basilea Pharmaceutica (OTCMKTS:BPMUF) has a market capitalization of $592.50 million and generates $154.86 million in revenue each year.
How many employees does Basilea Pharmaceutica have?: The company employs 143 workers across the globe.
Does Basilea Pharmaceutica have any subsidiaries?: The following companies are subsidiares of Basilea Pharmaceutica: Conec UK Limited.
Read More
How can I contact Basilea Pharmaceutica?: Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The official website for the company is www.basilea.com. The company can be reached via phone at (161) 606-1111, via email at investor_relations@basilea.com, or via fax at 41-61-606-1112.

This page (OTCMKTS:BPMUF) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial